Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HLX 53

Next Previous
Drug Profile

HLX 53

Alternative Names: Anti-TIGIT Fc fusion protein; HLX-53

Latest Information Update: 27 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henlix Biotech
  • Developer Shanghai Henlius Biotech
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 08 Aug 2024 Phase-II clinical trials in Liver cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) (IV) (NCT06349980, HLX53HCC201)
  • 17 Apr 2024 National Medical Products Administration approves IND for phase II trial in Liver cancer
  • 09 Apr 2024 Shanghai Henlius Biotech plans phase-II trial for Liver cancer (Combination therapy, Late-stage disease, Metastatic disease) in May 2024 (IV, infusion) (NCT06349980),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top